United Therapeutics Corporation (UTHR)
Company Info
| ISIN | US91307C1027 |
|---|---|
| CUSIP | 91307C102 |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | Jun 17, 1999 |
Highlights
| Market Cap | $17.90B |
|---|---|
| EPS (TTM) | $22.75 |
| PE Ratio | 17.62 |
| PEG Ratio | 1.73 |
| Total Revenue (TTM) | $2.76B |
| Gross Profit (TTM) | $2.45B |
| EBITDA (TTM) | $1.51B |
| Year Range | $208.62 - $417.82 |
| Target Price | $394.70 |
| Short % | 6.48% |
| Short Ratio | 6.65 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: UTHR vs. CTLT, UTHR vs. SPY, UTHR vs. COST, UTHR vs. VDE, UTHR vs. MID, UTHR vs. NBIX, UTHR vs. SCHG, UTHR vs. BBH, UTHR vs. SRPT, UTHR vs. WELL
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in United Therapeutics Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
United Therapeutics Corporation had a return of 82.11% year-to-date (YTD) and 75.34% in the last 12 months. Over the past 10 years, United Therapeutics Corporation had an annualized return of 12.33%, outperforming the S&P 500 benchmark which had an annualized return of 11.39%.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 82.11% | 25.48% |
| 1 month | 12.14% | 2.14% |
| 6 months | 46.85% | 12.76% |
| 1 year | 75.34% | 33.14% |
| 5 years (annualized) | 34.79% | 13.96% |
| 10 years (annualized) | 12.33% | 11.39% |
Monthly Returns
The table below presents the monthly returns of UTHR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -2.32% | 5.06% | 1.81% | 2.01% | 17.41% | 15.78% | -1.65% | 16.04% | -1.43% | 4.36% | 82.11% | ||
| 2023 | -5.37% | -6.51% | -8.97% | 2.75% | -8.86% | 5.25% | 9.95% | -7.56% | 0.67% | -1.33% | 7.69% | -8.38% | -20.93% |
| 2022 | -6.58% | -17.67% | 7.95% | -1.03% | 29.73% | 2.30% | -1.94% | -1.93% | -7.61% | 10.10% | 21.41% | -0.64% | 28.70% |
| 2021 | 7.93% | 2.05% | 0.05% | 20.50% | -7.77% | -3.49% | 1.40% | 18.11% | -14.10% | 3.35% | -0.66% | 14.03% | 42.35% |
| 2020 | 10.89% | 5.42% | -7.90% | 15.54% | 7.66% | 2.59% | -7.88% | -4.05% | -5.57% | 32.90% | -1.18% | 14.44% | 72.33% |
| 2019 | 5.90% | 9.50% | -7.06% | -12.61% | -18.13% | -7.04% | 1.51% | 4.19% | -3.40% | 12.65% | 2.69% | -4.53% | -19.12% |
| 2018 | -12.81% | -10.19% | -3.01% | -2.00% | -3.21% | 6.16% | 8.63% | 0.07% | 3.98% | -13.31% | 6.53% | -7.79% | -26.39% |
| 2017 | 14.08% | -9.72% | -8.35% | -7.15% | -3.83% | 7.31% | -1.03% | 1.87% | -10.41% | 1.19% | 9.61% | 13.82% | 3.15% |
| 2016 | -21.35% | -1.01% | -8.62% | -5.59% | 13.18% | -11.04% | 14.25% | 1.05% | -3.43% | 1.69% | 4.61% | 14.19% | -8.42% |
| 2015 | 8.99% | 9.86% | 11.21% | -7.39% | 15.05% | -5.32% | -2.64% | -11.07% | -12.87% | 11.73% | 4.09% | 2.61% | 20.94% |
| 2014 | -9.25% | -1.17% | -7.29% | 6.36% | -4.27% | -7.57% | 2.77% | 29.57% | 9.18% | 1.80% | 1.22% | -2.32% | 14.51% |
| 2013 | 0.88% | 10.99% | 1.77% | 9.71% | -0.43% | -1.01% | 13.84% | -5.37% | 11.20% | 12.26% | 4.28% | 22.50% | 111.68% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current risk-adjusted rank of UTHR is 93, placing it in the top 7% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the United Therapeutics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the United Therapeutics Corporation was 93.18%, occurring on Dec 10, 2001. Recovery took 2282 trading sessions.
The current United Therapeutics Corporation drawdown is 2.33%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -93.18% | Jul 13, 2000 | 352 | Dec 10, 2001 | 2282 | Jan 3, 2011 | 2634 |
| -60.3% | Apr 24, 2015 | 1068 | Jul 22, 2019 | 428 | Apr 1, 2021 | 1496 |
| -60.2% | Feb 28, 2000 | 36 | Apr 17, 2000 | 51 | Jun 29, 2000 | 87 |
| -47.37% | Apr 28, 2011 | 110 | Oct 3, 2011 | 451 | Jul 22, 2013 | 561 |
| -26.83% | Dec 12, 2022 | 116 | May 30, 2023 | 261 | Jun 12, 2024 | 377 |
Volatility
Volatility Chart
The current United Therapeutics Corporation volatility is 8.91%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of United Therapeutics Corporation compared to its peers in the Biotechnology industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for UTHR in comparison to other companies of the Biotechnology industry. Currently, UTHR has a PE value of 17.6. This PE ratio falls in the average range for the industry.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for UTHR in comparison to other companies of the Biotechnology industry. Currently, UTHR has a PEG value of 1.7. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for United Therapeutics Corporation.
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |